NOTED DRUG DEVELOPMENT AUTHORITY DR. HANS VAN BRONSWIJK EXPANDS PAREXEL CONSULTING'S EUROPEAN PRACTICE
BOSTON, MA, August 14, 2007 – PAREXEL Consulting, a business unit of PAREXEL International (NASDAQ: PRXL) and a leading global life sciences consultancy serving the bio/pharmaceutical and medical device industries, has appointed Dr. Hans Van Bronswijk to the position of Principal Consultant in its European Drug Development Practice. In this role, Dr. Van Bronswijk will advise clients on all aspects of clinical development and regulatory affairs. With in-depth knowledge of drug development and European Union (EU) regulatory procedures, Dr. Bronswijk will help PAREXEL clients effectively navigate the increasingly complex development and regulatory environment. Dr. Van Bronswijk served on the Dutch Medicines Evaluation Board (MEB) for nine years as Head of Clinical Assessment and was the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) member representing The Netherlands for six years.
“We expect that PAREXEL clients will benefit from Dr. Van Bronswijk’s internationally recognized drug development expertise and his unique combination of pan-European regulatory, medical, scientific, and pharmaceutical industry experience,” said Dr. Alberto Grignolo, Corporate Vice President, PAREXEL Consulting. “This appointment reinforces our leadership in helping clients achieve successful international product registrations, clinical and manufacturing performance excellence, and product safety.”
Dr. Van Bronswijk’s experience includes various positions within Novartis, most recently as Global Head of Regulatory Affairs for the Transplantation & Immunology business unit. Additionally, Dr. Van Bronswijk worked as a medical doctor for 16 years, as an internist and nephrologist, with an emphasis on transplant medicine and renal diseases.
“PAREXEL has an impressive reputation for innovation, expertise, and global capabilities in drug development,” Dr. Van Bronswijk commented. “I am proud to be joining the senior drug development consulting team in Europe and welcome the opportunity to advise PAREXEL clients on international regulatory affairs issues and the development process.”
# # #
About PAREXEL Consulting
PAREXEL Consulting is a leading life sciences consultancy that helps companies design and execute their biopharmaceutical and medical device product strategies through our unique fusion of scientific, regulatory, and business expertise. Our approach helps clients manage risk, and drives superior quality and performance for clients worldwide. The firm has approximately 270 employees in seven major office locations in the U.S. and Europe, and serves clients on a global basis. For further information visit: www.PAREXELConsulting.com. PAREXEL Consulting is a division of PAREXEL International.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has 6,485 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “expects”, “intends”, “appears”, “estimates”, “projects”, “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.